G

Genomed SA
WSE:GEN

Watchlist Manager
Genomed SA
WSE:GEN
Watchlist
Price: 25 PLN -1.57% Market Closed
Market Cap: 33m PLN
Have any thoughts about
Genomed SA?
Write Note

Genomed SA
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Genomed SA
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
G
Genomed SA
WSE:GEN
Operating Income
zł1.2m
CAGR 3-Years
39%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
M
Mabion SA
WSE:MAB
Operating Income
zł30.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
R
Read Gene SA
WSE:RDG
Operating Income
-zł979.2k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-1%
B
Bioton SA
WSE:BIO
Operating Income
zł1.9m
CAGR 3-Years
-63%
CAGR 5-Years
N/A
CAGR 10-Years
-20%
U
Urteste SA
WSE:URT
Operating Income
-zł6.4m
CAGR 3-Years
-74%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Synthaverse SA
WSE:SVE
Operating Income
zł6.8m
CAGR 3-Years
-1%
CAGR 5-Years
N/A
CAGR 10-Years
7%
No Stocks Found

Genomed SA
Glance View

Market Cap
33m PLN
Industry
Biotechnology

Genomed SA engages in the provision of medical diagnostic services. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2011-05-30. The company develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Company’s offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Company’s activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The firm also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.

GEN Intrinsic Value
25.37 PLN
Undervaluation 1%
Intrinsic Value
Price
G

See Also

What is Genomed SA's Operating Income?
Operating Income
1.2m PLN

Based on the financial report for Dec 31, 2023, Genomed SA's Operating Income amounts to 1.2m PLN.

What is Genomed SA's Operating Income growth rate?
Operating Income CAGR 5Y
-7%

Over the last year, the Operating Income growth was 249%. The average annual Operating Income growth rates for Genomed SA have been 39% over the past three years , -7% over the past five years .

Back to Top